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Background: Chronic infections with Pseudomonas aeruginosa are a leading cause of morbidity in patients 
with cystic ﬁbrosis (CF). The aim of tobramycin inhalation therapy in CF patients with chronic pulmonary 
infection is to deliver high amounts of drug directly to the site of infection. TOBI® is a tobramycin 
nebulizer solution (300 mg/5 ml) approved by FDA for maintenance therapy for patient with CF. The 20%
tobramycin sulfate solution was reported as the optimal and maximal concentration.
Methods: Nebulization of high strength tobramycin solution (20% tobramycin sulfate) (HSTS) has been 
assessed in this study by using different selected high performance nebulizer delivery systems: two 
different designs of jet nebulizers, and three new nebulizers based on vibrating mesh technology. The 
aerosol particle size distribution and output characteristics were measured for in vitro performance 
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1131. Introduction
Pulmonary infections are the primary cause of morbidity and
mortality among cystic ﬁbrosis (CF) patients. Pseudomonas aerugi-
nosa is the most common bacterial pathogen associated with pul-
monary exacerbations in CF [1], so antipseudomonal antibiotics
combinations often include aminoglycosides [2,3] as part of the
treatment regimen, due to their potent activity and low potential
for development of resistance [4]. Antibiotics in CF are used on an
intermittent basis to treat pulmonary exacerbations to lengthen the114
115
116interval between them [5e9]. Systemic antibiotic therapy is limited
by the poor penetration of most intravenously administered agents
into bronchial secretions, and the impairment of their biological
activity by purulent secretions. Moreover, repeated courses of
intravenous antibiotics increase risk of bacterial antibiotic resis-
tance and complications associated with prolonged use. The ma-
jority of clinical trials of inhaled antibiotics have investigated their
efﬁcacy as suppressive therapy in the period between acute exac-
erbations. Inhaled antibiotics can be used as maintenance treat-
ment for patients chronically infected with P. aeruginosa to improve
pulmonary function and reduce the frequency of hospital admis-
sion. Aminoglycoside antibiotics are among those commonly
aerosolized because they are chemically stable, have a long post-117
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130antibiotic effect, have a low background level of resistance, and
have an acceptable taste. Tobramycin is one of the aminoglycosides
with the lowest systemic toxicity.
Recently, the safety and efﬁcacy of inhaled tobramycin solution
300 mg/5 ml (TOBI)® were approved by FDA for maintenance
treatment of Pseudomonas aeroginosa lung infections in CF patients
[10e12]. The approved tobramycin inhalation regimen therapy is
300 mg twice daily, during three courses of 28 days. Serum
tobramycin concentration was 1 mg/L, measured 1 h after inhala-
tion of 300 mg tobramycin with a Pari LC Plus® nebulizer on days 3
and 10, during a treatment period of 28 days [13]. In another study,
the mean (SD) of tobramycin serum level was 1.27 mg/L (1.07) after
inhalation of single dose 600 mg tobramycin with Wisto Senior®
ultrasonic nebulizer [14]. Many assessed studies for tobramycin
nebulization have been reported [15e20].
Compared to intravenous therapy, these values are low. Plasma
tobramycin levels at least 8 mg/L are necessary to treat exacerba-
tions with intravenous administration. Toxic serum level of tobra-
mycin is > 12 mg/L, and this wide range between serum level of
inhaled tobramycin and toxic serum level encourages trials of
nebulized high strength dose of tobramycin to achieve the optimal
inhaled dose.
An in vitro study by Le Brun et al. [21,22] assessed nebulization
of several tobramycin sulfate solutions ranging from 5 to 30% (w/v),
delivered by 14 commercially available jet and ultrasonic nebu-
lizers. They reported that a 20% tobramycin sulfate solutionwas the
optimal and maximal concentration to be aerosolized, and the jet
nebulizer was most suitable. The delivery of a high amount of
tobramycin into the lungs is largely dependent upon nebulizer
performance, which is signiﬁcantly affected by the physicochemical
properties of drug solution such as osmolarity, pH, ionic strength,
viscosity, density, and surface tension.
In this present study, in vitro aerodynamic characterization of
the dose emitted during nebulization of high strength dose of
tobramycin by novel and jet nebulizer delivery systems has been
studied to determine optimum combinations for delivery of high
dose of tobramycin.
2. Materials and methods
2.1. Method of study
Nebulization of tobramycin high strength solution (200 mg/ml)
has been evaluated by using different selected high performance
nebulizer delivery systems. The most important characteristic for
nebulizer performance assessment is the aerosol particle size dis-
tribution and output that are produced by nebulizer device. The
methodology applied for the determination of the aerosol particle
size distribution and aerosol output was adapted from the current
European standard [23]. The nebulization time, simplicity of use,
cost, and cleaning and sterilization requirements are also important
characteristics for nebulizer performance. All measurements were
performed at ambient conditions.
2.2. Tobramycin solution
The aerosolized tobramycin formulation was tobramycin sulfate
(USP XXIII quality, Dumex-Alpharma A/S, Denmark) 200 mg/ml in
0.18% sodium chloride (w/v). The osmolarity and pH values of
tobramycin sulfate 20% are acceptable and tolerated for aerosolized
solutions. The osmolarity was 335 mmol/kg measured by 5500
Vapour pressure osmometer (Wescor, Inc., Logan, Utah, USA). Sul-
furic acid and sodium hydroxide were used to adjust the pH of the
drug solution to 6, measured by Corning M240 pH meter (Ciba
Corning Diagnostic, Surbury, Suffolk, UK). All physicalmeasurements were performed at ambient temperature.
2.3. Nebulizer devices
Different nebulizer systems were used: two different designs of
jet nebulizers and three new nebulizers based on vibrating mesh
technology. The jet nebulizers were the breath-enhanced jet
nebulizer Pari LC Plus® attached to a PariBoyN® compressor and the
constant output jet nebulizer Sidestream® attached to Porta-Neb®
compressor and compressed air cylinder at different gas ﬂow rates:
12 and 16 L/min. The new nebulizers were the NE-U22 Omron®
static mesh nebulizer (low and high frequencies), and the Aeroneb®
Go vibrating mesh nebulizer. The nebulizer ﬁll volumes were 5 ml
and 2.5 ml for jet and new nebulizers, respectively.
The Sidestream® attached to Porta-Neb® compressor is fast,
accurate drug delivery every time. It is a constant-output open-vent
jet nebuliser. The open vent on the top of nebuliser chamber im-
proves aerosol output by allowing the negative pressure to suck
extra air into the chamber. This markedly increases the air ﬂow out
of the nebuliser and pushes out more small droplets to be inspired.
The aerosol is produced or released constantly during inspiration
and expiration. It is a reusable nebuliser and can be cleaned in the
dishwasher, boiled or autoclaved.
The PARI LC Plus nebulizer is the “gold standard” for aerosolized
medication delivery.
It is a breath-enhanced open-vent jet nebuliser that uses two
valves to maximise aerosol delivery and minimise medication
wastage. The inspiratory valve is opened during inspiration to allow
extra air to be sucked through the nebuliser chamber and closed
during exhalation to decrease air ﬂow through the chamber. It is
designed for children as well as adults and works with any
compressor. It is a reusable nebuliser that is recommended for six
months use and it can be cleaned in the dishwasher, boiled or
autoclaved.
The MicroAir® NE-U22 nebuliser uses an ultrasonic transducer
to generate vibration (180 kHz) of the drug solution and push the
droplets through the static meshwhich can then be inhaled directly
by the patient. Unlike jet and ultrasonic nebulisers, the aerosol is
not recycled in the mesh nebuliser. The mesh cannot be disinfected
by an autoclave process and should be submerged in a 0.1% ben-
zalkonium solution.
The Aeroneb® Go nebuliser has a novel design and generates
aerosol using the OnQ™ electronic micropump. It consists of a
domed aperture plate with precision-formed holes (1000 holes)
and a vibrational element which vibrates at 100 kHz. This creates a
micro-pumping action producing a ﬁne particle, low velocity
aerosol using no propellants or compressors. It cannot be dis-
infected by an autoclave process and there are no speciﬁc recom-
mendations for disinfecting.
2.4. Aerosol particle size distribution
The Aerosol particle size is an important characteristic of
nebulizer performance. Particles too large do not reach the lower
respiratory tract, whereas particles too small are exhaled [24e26].
It has been shown that smaller particles are produced at higher
nebulizer ﬂow [27]. The Aerosol particle size should be 2e5 mm for
air way deposition, and 1e2 mm for parenchymal deposition [28].
The Aerosol particle size produced by the nebulizer was deter-
mined by using the eight-stage Marple 298 cascade impactor
(Copley Scientiﬁc Limited, UK).
The Aerosol particle size is often expressed in terms of mass
median aerodynamic diameter (MMAD). The amount of tobramycin
extracted from cascade ﬁlters was determined by HPLC.
Mass Median Aerodynamic Diameter (MMAD) is deﬁned as the
Table 1
Summary ofmean (SD, n¼ 10) aerosol particle size distribution characteristics during nebulization tobramycin high strength solution of by selected nebulizer delivery systems.
Nebulizer device MMAD mm GSD mm Fine particles <5 mm (mg) % FPF VMD mm
Sidestream® Porta-Neb compressor 2.7 ± 0.3 2.5 ± 0.1 2.6 ± 0.2 47.6 ± 3.5 2.6 ± 0.2
Sidestream® (Flow rate 12 L/min) 1.5 ± 0.01 2.2 ± 0.5 8.2 ± 0.6 68.8 ± 2.5 3.3 ± 0.4
Sidestream® (Flow rate 16 L/min) 1.2 ± 0.1 2.5 ± 0.2 10.7 ± 1.6 77.6 ± 2.3 3.1 ± 0.2
Pari LC Plus® PariBoy compressor 1.9 ± 0.1 2.4 ± 0.1 7.4 ± 0.5 59.6 ± 0.8 3.3 ± 0.2
Aeroneb Go® 2.1 ± 0.1 2.1 ± 0.1 9.2 ± 1 59 ± 1.7 2.7 ± 0.2
NE-U22 Omron® (High frequency) 2.7 ± 0.3 2.3 ± 0.1 5.6 ± 0.4 47.3 ± 3.8 2.3 ± 0.3
NE-U22 Omron® (Low frequency) 2.3 ± 0.2 1.7 ± 0.1 2 ± 0.4 57 ± 4.4 2 ± 0.2
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92diameter at which 50% of the particles by mass are larger and 50%
are smaller.
Geometric Standard Deviation (GSD) is a measure of the spread
of an aerodynamic particle size distribution.
The size distribution was expressed in terms of the volume
median diameter (VMD), which is the value of the particle size that
divides the population into two equal halves. The VMD is directly
related to the mass median diameter (MMD) by the density of the
particles.
According to Clark and Borgstrom [29], the cumulative deposi-
tion data were plotted against stage cut-off diameter, and ﬁtted
with a logarithmic regression curve to determine the particle size at
50% of the accumulated deposition (Mass median aerodynamic
diameter, MMAD), geometric standard division (GSD), and volume
median diameter (VMD), and recorded as the mean of ten
determinations.93
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1072.5. Aerosol output
The performance of nebulizer efﬁciency was evaluated using
high dose of aerosolized tobramycin (20%) by determination of the
aerosol output characteristics that include respirable inhaled mass,
aerosol output rate, deposited dose, nebulization time, and residual
dose volume using adult breathing simulator modelling (Pari Res-
piratory Equipment, Inc). These parameters were recorded as the
mean of ten determinations. The respirable inhaled mass was
collected on a ﬁlter placed between the nebulizer and breathing
simulator modelling under conditions of simulated normal adult
breathing (tidal volume 500 ml, 15 breaths/min, and inspirator-
y:expiratory ratio 50%) then the extracted amount and the residual0
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Fig. 1. Mean (SD, n ¼ 10)) MMAD obtained by nebulizer systems during nebulization
of high strength dose of tobramycin. Key: SP ¼ Sidestream®/PotaNeb® compressor, S12
and S16 Sidestream®/air cylinder at ﬂow rate 12 and 16 L/min, PP ¼ Pari LC Plus®/
PariBoy®, OL and OH ¼ low and high frequency of NE-U22 Omron®, and
AG ¼ Aeroneb® Go.
108
109
110medication left in the device were determined by the developed
HPLC method. The duration of nebulization (Treatment time) was
measured one minute past sputter (jet nebulizers) using stopwatch
or to the end of aerosol generation (ultrasonic nebulizers and
Aeroneb Go). The aerosol particle size distribution and aerosol
output were determined at ambient conditions (temperature
23 ± 2 C, relative humidity 45% r.h to 75% r.h, and pressure from
86 kPa to 106 kPa).
2.6. Tobramycin assay
The tobramycin concentration was determined by using vali-
dated HPLC method following pre-column derivatization with
ﬂuorescein isothiocyanate (FITC) [30]. The Guideline on Bio-
analytical Method Validation. EMEA/CHMP/EWP/192217/2009, 21
July 2011 [31] was used as a guide to validated the analytical
method.
3. Results and discussion
Le Brun et al. [32] have reported that 20% tobramycin sulfate in
normal saline (osmolarity 483 mmol/kg and pH 7.6) was the
optimal and maximal concentration to be aerosolized. In this study,
0.18% NaCl was used with 20% tobramycin sulfate to achieve the
osmolarity of drug solution to 335 mmol/kg. This value will be
tolerated after inhalation, since an osmolarity of an antibiotic so-
lution in the range of 150e550 mmol/kg is acceptable [33].
Sulfuric acid and sodium hydroxide were added to adjust the pH
of drug solution to 6, which is an acceptable value for aerosolized
solutions. After jet nebulization, the osmolarity was increased to
400mmol/kg in Sidestream® and Pari LC Plus® jet nebulizers due to
evaporation of the solvent, while the pH value was constant.
Although the osmolarity of drug solution rose to 400 mmol/kg0
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Fig. 2. Mean (SD, n ¼ 10) inhalation rate of tobramycin produced by different nebu-
lizer systems during nebulization of high strength dose of tobramycin.
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Table 2
Summary of means (SD, n ¼ 10) aerosol output characteristics during nebulization tobramycin high strength solution of by different nebulizer delivery systems.
Nebulizer device Fill volume Nebulization time
(min)
Inhalation rate
(mg/min)
Respirable inhaled
Mass (mg)
Respirable inhaled
mass %
Residual of dose
volume %
Sidestream® Porta-Neb compressor 5 ml 18 ± 0.3 7.4 ± 0.3 62.9 ± 2.2 9.6 ± 0.3 51.3 ± 3.5
Sidestream®
(Flow rate 12 L/min)
5 ml 11.5 ± 0.2 9.16 ± 0.4 72.57 ± 3.3 11 ± 0.5 55.5 ± 3.7
Sidestream®
(Flow rate 16 L/min)
5 ml 7.5 ± 0.2 11.68 ± 1.3 68 ± 7.7 10.4 ± 1.2 63.9 ± 3.9
Pari LC Plus® PariBoy compressor 5 ml 17 ± 1.1 8.97 ± 0.9 90.9 ± 8.6 13.6 ± 1.3 46.9 ± 2.5
NE-U22 Omron®
(Low frequency)
2.5 ml 28 ± 1.3 5.18 ± 0.5 82.6 ± 7.8 20.6 ± 1.1 7.8 ± 0.5
NE-U22 Omron®
(High frequency)
2.5 ml 13 ± 0.5 11 ± 0.6 67.4 ± 3.8 25.2 ± 2.4 2.3 ± 0.3
Aeroneb Go® 2.5 ml 7.3 ± 0.2 18 ± 1.1 78.4 ± 5 23.9 ± 1.5 33.2 ± 2.2
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Fig. 3. Mean (SD, n ¼ 10) respirable inhalation mass of tobramycin produced by different nebulizer systems during nebulization of high strength dose of tobramycin.
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Fig. 4. Mean (SD, n ¼ 10) residual volume percentage of tobramycin after nebulization of high strength dose of tobramycin by different nebulizer systems.
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Fig. 5. Mean (SD, n ¼ 10) nebulization time of nebulization of high strength dose of tobramycin by different nebulizer systems.
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130during nebulization, it was still within the acceptable range. The
particle size distribution is dependent on the type of nebulizer or
the combination of compressor and nebulizer [34e37] In the ex-
periments, the Sidestream® was combined with PortaNeb®
compressor (ﬂow rate 6.8 L/min) and compressed air cylinder at
ﬂow rate 12 and 16 L/min. The Pari LC Plus® was combined with
PariBoyN® compressor (ﬂow rate 7 L/min). Although all tested
nebulizers produced droplets within the respirable size, the
smallest particle size was observed for Sidestream® at ﬂow rate
16 L/min which can be explained by the higher ﬂow rate. The low
frequency of NE-U22 Omron® produced droplet particles smaller
than high frequency. The heterodispersity of aerosol produced from
vibrating mesh nebulizers was less than those produced from jet
nebulizers. All the nebulized aerosols were polydispersed with
span values ranging from 2.58 to 3.28 mm for jet nebulizers, and
1.57e2.65 mm for vibrating mesh nebulizers. The mean (SD) of
highest percentage of ﬁne particles (<5 mm) was 77.64 (2.3) % for
Sidestream®, at ﬂow rate 16 L/min. The particle size distribution
characteristic measurements are summarized in Table 1. When
comparing the nebulizers, the particle size distribution results
showed that all may be suitable for inhalation of a 20% tobramycin
sulfate solution, as shown in Fig. 1.
Increasing the driving gas ﬂow through jet nebulizers will in-
crease the drug output and decrease the nebulization time [38]. In
tested jet nebulizers, the inhaled amount of tobramycin in the ﬁrst
minute was increased, while the total inhaled amount decreased
with increasing ﬂow rate (6.8e16 L/min). The PortaNeb®
compressor was the optimum combination with the Sidestream®
jet nebulizer. However, the highest respirable inhaled mass was for
Pari LC Plus® combined with PariBoyN® compressor, with mean
(SD) 90.85 (8.6) mg. The NE-U22 Omron® (low and high frequency)
and Aeroneb Go® were showed a high percentage of respirable
inhaled mass with ﬁll volume less than the jet nebulizers. The drug
wastage was increased with jet nebulizers due to evaporation of
solvent during jet nebulization, leading to a gradual increase in the
concentration of drug solution left behind.
The mean (SD) of highest drug wastage percentage was 63.9
(3.9) % for Sidestream® jet nebulizer combined with compressed air
cylinder at ﬂow rate 16 L/min, while the lowest was 2.3 (0.26) % for
NE-U22 Omron® (high frequency). The aerosol output character-
istics are summarized in Table 2. When the results data of the
particle size distribution and output measurements are combined,
the high frequency NE-U22 Omron® and Aeroneb Go® are preferredto nebulize 20% tobramycin sulfate. As shown in Figs. 3e5, the NE-
U22 Omron® high frequency showed high inhalation rate, high
respirable mass, less drug wastage, and reasonable nebulization
time, while Aeroneb Go® showed the shortest nebulization time.
When compared to TOBI®, the respirable inhaled mass (<5 mm)
produced by nebulization of tobramycin sulfate 20% was increased
to more than 40% (see Fig. 2).
4. Conclusion
In conclusion, the high strength tobramycin solution (20%
tobramycin sulfate) can be nebulized by all tested nebulisers but
the high frequency NE-U22 Omron® and Aeroneb Go® are more
efﬁcient. When the high strength tobramycin solution compared to
TOBI®, the respirable inhaled dose was increased to more than 73%.
The particle size distribution characteristic measurements
showed that all tested nebulizers may be suitable for inhalation of a
20% tobramycin sulfate solution while the aerosol output mea-
surements showed that the NE-U22 Omron® high frequency and
Aeroneb Go® are the best.
The NE-U22 Omron® high frequency showed high inhalation
rate, high respirable mass, less drug wastage, and reasonable
nebulization time, while Aeroneb Go® showed the shortest nebu-
lization time.
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